Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Musculoskeletal
Disease Category: Multiple Sclerosis
Trial Information
Add-on Therapy of an oral medication for patients with Multiple Sclerosis, currently using Avonex, Betaseron, or Rebif.
A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy with Rebif New Formulation in Multiple Sclerosis Subjects with Active Disease
This two year study is evaluating the efficacy of two doses of an oral medication compared to placebo when added to an interferon (Avonex, Betaseron & Rebif) in treating Relapsing Remitting Multiple Sclerosis. Patients must currently be taking one of the aforementioned medications for at least one year.
Major Inclusion/ Exclusion Criteria:
- Ages 18-65
- Confirmed diagnosis of Relapsing Remitting Multiple Sclerosis and taking Avonex, Betaseron & Rebif for the past year
- Must never have taken Tysabri
- Must be able to walk without assistance for 100 yards
- Must have had at least one relapse within 48-weeks prior to beginning the study
Alpine Clinical Research Center
1000 Alpine Avenue, Suite 200
Boulder, CO 80304
Phone: 303-443-7229
EMail: anita@alpineresearch.com
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
